Andrada Mining acquisition elevates the miner to emerging mid-tier status. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,356.00
Bid: 12,390.00
Ask: 12,394.00
Change: 28.00 (0.23%)
Spread: 4.00 (0.032%)
Open: 12,364.00
High: 12,454.00
Low: 12,322.00
Prev. Close: 12,328.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON BRIEFING: UK retail sales up; Hunt "comfortable" with recession

Fri, 26th May 2023 07:57

(Alliance News) - Stocks in London are expected to kick off the final trading day of a fraught week with a minor gain, though US debt ceiling uncertainty continues to temper sentiment.

President Joe Biden declared Thursday the US would avoid a disastrous credit default, even as lawmakers went on a 10-day break without a deal on raising the nation's borrowing limit to keep paying the bills.

There are seven days until June 1 – the earliest possible point when the government estimates it could run out of money to service its debts – and missed loan repayments would likely spark a downturn, roiling world markets.

In local economic news on Friday, UK retail sales edged up on a monthly basis in April, while an annual decline softened, according to the Office for National Statistics. Meanwhile, the UK's chancellor reaffirmed his support for the Bank of England's monetary policy moves.

On the corporate side, IAG's British Airways flights at Heathrow were disrupted by a technical issue on Thursday, while AstraZeneca shared some positive clinical trial results. IntegraFin reported weaker half-year earnings, as well as a slowdown in net inflows at its Transact arm.

Here is what you need to know at the London market open:

----------

MARKETS

----------

FTSE 100: called up 14.5 points, 0.2%, at 7,585.37

----------

Hang Seng: financial markets in Hong Kong closed for Buddha Day

Nikkei 225: closed up 0.4% at 30,916.31

S&P/ASX 200: closed up 0.2% at 7,154.80

----------

DJIA: closed down 35.27 points, 0.1%, at 32,764.65

S&P 500: closed up 0.9% at 4,151.28

Nasdaq Composite: closed up 1.7% at 12,698.09

----------

EUR: up at USD1.0737 (USD1.0723)

GBP: up at USD1.2337 (USD1.2330)

USD: down at JPY139.74 (JPY139.85)

Gold: up at USD1,949.11 per ounce (USD1,945.11)

Oil (Brent): largely flat at USD76.18 a barrel (USD76.15)

(changes since previous London equities close)

----------

ECONOMICS

----------

Friday's key economic events still to come:

08:30 EDT US personal consumption expenditures

10:00 EDT US University of Michigan survey of consumers

----------

UK retail sales edged up on a monthly basis in April, while an annual decline softened, according to the Office for National Statistics on Friday. The ONS estimated that retail sales volumes in April rose 0.5% from the previous month, after a downwardly revised fall of 1.2% in March. The reading was slightly higher than FXStreet-cited market consensus of 0.3%. On an annual basis, retail sales volumes fell 3.0% in April, compared to a downwardly revised fall of 3.9% in March. Market consensus had expected a 2.8% fall in April, while March was initially reported as a 3.1% decline.

----------

UK Chancellor Jeremy Hunt said he is "comfortable" with the UK falling into a recession, if that's what is needed to tackle elevated inflation, according to Sky News. "If we want to have prosperity, to grow the economy, to reduce the risk of recession, we have to support the Bank of England in the difficult decisions that they take," Hunt told Sky News. As chancellor, Hunt said he has to make "difficult decisions" to balance the UK's books, "so that the markets, the world can see that Britain is a country that pays its way". "All these things mean that monetary policy at the Bank of England (and) fiscal policy by the chancellor are aligned," Hunt added.

----------

BROKER RATING CHANGES

----------

Berenberg raises Sabre Insurance to 'buy' (hold) - price target 153 (93) pence

----------

RBC cuts Halfords Group to 'sector perform' (outperform) - price target 220 (230) pence

----------

Morgan Stanley raises Rio Tinto to 'overweight' - price target 5,800 pence

----------

COMPANIES - FTSE 100

----------

International Consolidated Airlines unit British Airways has apologised after an IT issue caused the cancellations of domestic and European flights on Thursday, as Britain heads into the Bank Holiday weekend. There were more than 50 cancelled British Airways flights departing Heathrow on Thursday, with the airline urging passengers to check their flight status before going to the airport on Friday. There were more than 20 flights that had been cancelled or still currently delayed that were meant to land at Heathrow on Thursday. Some flights that are due to depart Friday evening have been notified their flights are delayed, adding to the stress for customers.

----------

AstraZeneca reported positive high-level results from this DUO-E phase III trial into treatment for endometrial cancer. The trial looked at Imfinzi in combination with platinum-based chemotherapy, followed by either Imfinzi and Lynparza or Imfinzi alone as a maintenance therapy. The treatment "demonstrated a statistically significant and clinically meaningful improvement in progression-free survival compared to standard-of-care chemotherapy alone in patients with newly diagnosed advanced or recurrent endometrial cancer," Astra said.

----------

COMPANIES - FTSE 250

----------

IntegraFin reported on its half-year ended March 31, with revenue little changed year-on-year at GBP66.5 million, compared to GBP67.0 million. Pretax profit slipped 12% to GBP27.9 million from GBP31.7 million. The Transact investment platform owner said net inflows there amounted to GBP1.6 billion, slowing from GBP2.7 billion a year before, though client numbers rose 4.1% year-on-year to a record of 228,232 from 218,787. The firm said the cost guidance provided in December remains unchanged. It maintained its interim dividend payout at 3.2 pence per share. "The digitalisation programme for the Transact platform is well underway and is being positively received. The recruitment of IT and software professionals is progressing well, though at a slower pace than originally planned, whilst the market for IT professionals remains competitive," it said.

----------

Asos late Thursday announced plans to boost its balance sheet through a new long-term GBP275 million financing facility alongside a GBP75 million placing as it continues to restructure the business. The online fashion retailer said the new capital structure provides increased flexibility and simplicity under a single lender. Asos has entered into a GBP200 million senior term loan and a GBP75 million super senior revolving facility with specialist lender Bantry Bay Capital through to April 2026, which will replace the existing GBP350 million revolving credit facility which was due to expire in November 2024. The GBP75 million placing will be priced at 418.1 pence and there will be a separate retail offer of up to GBP5 million. Back in October, Asos announced a turnaround plan. It said it would look to improve inventory management, reduce its costs and "reinforce" its leadership team and culture. The plan was one of Jose Calamonte's first acts as chief executive. But some City analysts felt a fundraise would be required to get the ball rolling.

----------

OTHER COMPANIES

----------

AIM-listed digital publisher XLMedia warned that it expects current softness in the market to persist into the early summer. Despite a "strong start" to the first quarter in the US, it expects first-half revenue to fall behind the prior year - which had benefitted from the launch of online sports betting in New York. "The launch of online sports betting in Massachusetts in mid-March, after the NFL season ended, while solid, did not see the spike in revenues normally seen on a state launch," it said. The acquisition spend by operators in the first half is not comparable with the previous year, XLMedia noted, with "less generous" promotions available to attract new customers. It said trading in Europe has been in line with expectations, supported by the Cheltenham and Aintree horse racing festivals in the UK. It will update further on the first half in late-July.

----------

Paris police fired tear gas to disperse climate protesters trying to block an annual general meeting of French oil firm TotalEnergies. After giving three warnings on loudhailers, officers used tear gas on the activists, who sat on the road outside the meeting venue in an upscale Paris district, in a bid to stop people entering. Dozens of protesters had converged around the Salle Pleyel venue from dawn, in a protest called by a coalition of non-governmental organisations. They chanted slogans such as "All we want is to knock down Total" and "One, two and three degrees, we have Total to thank".

----------

By Elizabeth Winter, Alliance News senior markets reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
27 Jun 2024 13:00

German vaccine panel endorses Astra-Sanofi's RSV shot for infants

FRANKFURT, June 27 (Reuters) - Germany's influential vaccine advisory panel said on Thursday all infants in the country should receive AstraZeneca and Sanofi's antibody therapy to protect them against the common respiratory infection RSV.

Read more
26 Jun 2024 08:40

TOP NEWS: AstraZeneca's Tagrisso plus chemo gets approval in China

(Alliance News) - AstraZeneca PLC on Wednesday celebrated the approval of Tagrisso plus chemotherapy for a cancer form in China, a day after a similar approval in Japan.

Read more
25 Jun 2024 09:05

TOP NEWS: AstraZeneca details mixed findings from cancer drug trials

(Alliance News) - AstraZeneca PLC on Tuesday announced a mixed bag of results for two of its leading cancer drugs Imfinzi and Tagrisso.

Read more
25 Jun 2024 07:48

LONDON BRIEFING: Mixed bag for Astra drug; Landsec ups Bluewater stake

(Alliance News) - London's FTSE 100 is set to tread water on Tuesday, with a slump for US tech shares overnight keeping a lid on enthusiasm.

Read more
25 Jun 2024 07:17

AstraZeneca posts mixed results from recent Imfinzi trials

(Sharecast News) - AstraZeneca announced contrasting results from two phase three trials involving its immunotherapy drug 'Imfinzi', or durvalumab, on Tuesday.

Read more
24 Jun 2024 15:40

US Supreme Court gives pharma companies a chance to thwart terrorism-funding lawsuit

WASHINGTON, June 24 (Reuters) - The U.S. Supreme Court gave a boost on Monday to a challenge by 21 pharmaceutical and medical equipment companies led by AstraZeneca to a lawsuit accusing them of illegally helping to fund terrorism that killed or injured hundreds of American troops and civilians in Iraq.

Read more
24 Jun 2024 14:56

US Supreme Court gives pharma companies a chance to thwart terrorism-funding lawsuit

WASHINGTON, June 24 (Reuters) - The U.S. Supreme Court gave boost on Monday to a challenge by 21 pharmaceutical and medical equipment companies led by AstraZeneca to a lawsuit accusing them of illegally helping to fund terrorism that killed or injured hundreds of American troops and civilians in Iraq.

Read more
20 Jun 2024 10:56

TOP NEWS: AstraZeneca's Truqap gets OK from EU for breast cancer form

(Alliance News) - AstraZeneca PLC on Thursday said that the EU approved its prescription medicine Truqap, in combination with hormonal therapy Faslodex, for the treatment of a form of breast cancer.

Read more
18 Jun 2024 09:33

TOP NEWS: AstraZeneca disappointed by breast cancer drug trial results

(Alliance News) - AstraZeneca PLC on Tuesday said findings from a breast cancer drug trial showed that Truqap did not meet its primary endpoints.

Read more
18 Jun 2024 07:51

LONDON BRIEFING: Ashtead profit declines; Whitbread sales rise

(Alliance News) - London's FTSE 100 is called to open higher on Tuesday, taking confidence from a decent showing for US equities overnight, with inflation data and central bank decisions the key plot points as the week progresses.

Read more
18 Jun 2024 07:17

AstraZeneca trial fails to treat 'challenging' breast cancer

(Sharecast News) - AstraZeneca announced on Tuesday that the phase three 'CAPItello-290' trial for 'Truqap', or capivasertib, in combination with paclitaxel did not achieve its primary endpoints.

Read more
17 Jun 2024 09:09

TOP NEWS: Astra's Imfinzi plus chemo approved for cancer form in US

(Alliance News) - AstraZeneca PLC on Monday said it secured a new US approval for cancer treatment Imfinzi, also known as durvalumab, hailing an "important new option" for patients.

Read more
17 Jun 2024 07:48

LONDON BRIEFING: Astra gets US drug approval; Ascential trades in line

(Alliance News) - London's FTSE 100 is called to open solidly higher on Monday, recovering some poise after a tricky week, with eyes turning to the Bank of England.

Read more
17 Jun 2024 07:23

IN BRIEF: AstraZeneca gets positive cancer test results for Calquence

AstraZeneca PLC - Cambridge, England-based pharmaceutical maker - Reports promising test results for one of its cancer therapies. The Echo phase III trial shows that Calquence, when used in combination with bendamustine and rituximab, demonstrates a clinically meaningful improvement in progression-free survival in patients with untreated mantle cell lymphoma. Compared to standard-of-care chemoimmunotherapy, the combination with Calquence, whose generic name is acalabrutinib, shows a 27% reduced risk of disease progression or death. Mantle cell lymphoma is rare and typically aggressive form of non-Hodgkin lymphoma, Astra explains.

Read more
17 Jun 2024 07:15

AstraZeneca's Imfinzi gets US approval for endometrial cancer patients

(Sharecast News) - AstraZeneca said its Imfinzi cancer treatment had been approved in the US as treatment for adult patients with primary advanced or recurrent endometrial cancer.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.